Abstract

Paramagnetic rim lesions (Rim+) identified on susceptibility-sensitive MRI have recently emerged as a specific biomarker of chronic active inflammation in Multiple Sclerosis (MS) and are associated with long-term disability progression. However, susceptibility imaging and expert interpretation remain limited to specialized centers, visual assessment is time-consuming and variable, and the low prevalence of Rim+ lesions poses severe class imbalance challenges for automated analysis. We propose FRODO, a 3D Fusion framework for Rim lesion classificatiOn using multimodal Deep-learning neurOimaging, designed for lesion-level Rim+/Rim- classification from Quantitative Susceptibility Mapping (QSM) and FLAIR MRI. The architecture explicitly models modality asymmetry by treating QSM as the primary susceptibility-driven signal and conditioning it with FLAIR-derived structural context. To improve robustness under limited data, we employ self-supervised multimodal pretraining followed by supervised fine-tuning with contrastive regularization. The method was evaluated on a clinically acquired cohort of 88 people with MS with expert lesion annotations as reference standard. Results highlight improved performance compared to prior architectures, supporting the effectiveness of asymmetric multimodal modeling for automated chronic active lesion identification.

Links to Paper and Supplementary Materials

Main Paper (Open Access Version): https://papers.miccai.org/miccai-2026/paper/5533_paper.pdf

SharedIt Link: Not yet available

SpringerLink (DOI): Not yet available

Supplementary Material: Not Submitted

Link to the Code Repository

https://github.com/veronicapignedoli/FRODO

Link to the Dataset(s)

N/A

BibTex

@InProceedings{PigVer_3D_MICCAI2026,
        author = { Pignedoli, Veronica AND Boffa, Giacomo AND Noceti, Nicoletta AND Inglese, Matilde AND Odone, Francesca AND Moro, Matteo},
        title = { { 3D Classification of Paramagnetic Rim Lesions in Multiple Sclerosis via Asymmetric QSM–FLAIR Modeling } },
        booktitle = {Medical Image Computing and Computer Assisted Intervention -- MICCAI 2026},
        year = {2026},
        publisher = {Springer Nature Switzerland},
        volume = {LNCS 16885},
        month = {September},
        page = {pending}
}


Reviews

Review #1

  • Please describe the contribution of the paper

    This paper proposes a 3D multimodal deep learning framework for lesion-level classification of paramagnetic rim lesions (Rim+) in multiple sclerosis using QSM and FLAIR MRI. The method introduces an asymmetric multimodal design that treats QSM as the primary susceptibility-driven signal and conditions it with FLAIR via spatial FiLM. To address limited data and strong class imbalance, the framework incorporates self-supervised cross-modal pretraining and supervised contrastive regularization.

  • Please list the major strengths of the paper: you should highlight a novel formulation, an original way to use data, demonstration of clinical feasibility, a novel application, a particularly strong evaluation, or anything else that is a strong aspect of this work. Please provide details, for instance, if a method is novel, explain what aspect is novel and why this is interesting.
    1. Well-motivated clinical problem. Automated identification of paramagnetic rim lesions is clinically important and challenging, with clear relevance for disease characterization and prognosis in multiple sclerosis.
    2. Reasonable and task-aligned multimodal design. The asymmetric QSM–FLAIR formulation is well justified from a physiological perspective, and the use of FiLM-based conditioning provides an intuitive mechanism to incorporate structural context while preserving susceptibility-specific information.
    3. Careful experimental setup. The use of a clinically acquired cohort, patient-level cross-validation, and appropriate evaluation metrics (particularly PR-AUC under strong class imbalance) strengthens the validity of the study.
    4. Meaningful empirical improvements. The method shows clear gains over prior approaches, especially in PR-AUC and precision, which are important for rare lesion detection.
  • Please list the major weaknesses of the paper. Please provide details: for instance, if you state that a formulation, way of using data, demonstration of clinical feasibility, or application is not novel, then you must provide specific references to prior work.
    1. Methodological novelty is moderate. The proposed framework mainly combines existing components, including 3D CNN backbones, FiLM conditioning, self-supervised pretraining, and contrastive learning. The contribution lies more in their integration for this specific task rather than in fundamentally new methodology.
    2. Comparison to broader PRL literature is limited. The evaluation focuses primarily on QSMRim-Net and a ResNet baseline. Additional comparisons with other recent PRL detection/classification approaches (e. g. , studies such as PMC:12516162) would better contextualize the proposed method and strengthen claims of improved performance.
    3. Limited generalization assessment. All experiments are conducted on a single-center cohort. While the evaluation protocol is well designed, external validation on independent datasets would be important to assess robustness across acquisition settings.
  • Please rate the clarity and organization of this paper

    Good

  • Please comment on the reproducibility of the paper. Please be aware that providing code and data is a plus, but not a requirement for acceptance.

    The authors claimed to release the source code and/or dataset upon acceptance of the submission.

  • Based on your review and your understanding of the MICCAI Scientific Code of Ethics, do you believe this submission may involve a potential ethics concern or violation?

    N/A

  • Optional: If you have any additional comments to share with the authors, please provide them here. Please also refer to our Reviewer’s guide on what makes a good review and pay specific attention to the different assessment criteria for the different paper categories: https://conferences.miccai.org/2026/en/REVIEWER-GUIDELINES.html

    N/A

  • Rate the paper on a scale of 1-6, 6 being the strongest (6-4: accept; 3-1: reject). Please use the entire range of the distribution. Spreading the score helps create a distribution for decision-making.

    (5) Accept — should be accepted, independent of rebuttal

  • Please justify your recommendation. What were the major factors that led you to your overall score for this paper?

    Overall, this paper addresses a clinically relevant and technically challenging problem with a well-designed multimodal framework and solid experimental validation. The asymmetric modeling of QSM and FLAIR is intuitive and supported by meaningful improvements, particularly under severe class imbalance. While the methodological novelty is somewhat incremental and comparisons could be more comprehensive, the work provides practical value for automated PRL analysis. I would support acceptance.

  • Reviewer confidence

    Very confident (4)

  • [Post rebuttal] After reading the authors’ rebuttal, please state your final opinion of the paper.

    N/A

  • [Post rebuttal] Please justify your final decision from above.

    N/A



Review #2

  • Please describe the contribution of the paper

    This paper presents an end‑to‑end 3D multimodal deep learning framework for lesion‑level classification of paramagnetic rim (Rim+) versus non‑rim (Rim−) lesions in multiple sclerosis using QSM and FLAIR MRI. The method explicitly models modality asymmetry by leveraging QSM as the primary susceptibility‑driven signal and conditioning it with FLAIR‑based structural context, complemented by self‑supervised pretraining and contrastive regularization. The experimental results demonstrate improved Rim+ classification performance on a clinically representative dataset characterized by strong class imbalance.

  • Please list the major strengths of the paper: you should highlight a novel formulation, an original way to use data, demonstration of clinical feasibility, a novel application, a particularly strong evaluation, or anything else that is a strong aspect of this work. Please provide details, for instance, if a method is novel, explain what aspect is novel and why this is interesting.
    • The paper is clearly written, well structured, and easy to follow.
    • The proposed methodology is technically sound and well aligned with topics of interest to the MICCAI community.
    • The experimental evaluation suggests that the proposed approach can substantially improve Rim+ lesion classification performance compared to prior methods.
  • Please list the major weaknesses of the paper. Please provide details: for instance, if you state that a formulation, way of using data, demonstration of clinical feasibility, or application is not novel, then you must provide specific references to prior work.
    • The cohort size used for training, validation, and testing is relatively small, which makes it difficult to assess the broader clinical impact and robustness of the proposed method.
    • The absence of a separately held, fully independent test set limits the assessment of generalizability across sites or imaging protocols.
    • In Table 1, the effect of the FLAIR modality is not clearly isolated. It would be helpful to clarify whether the same QSM/FLAIR input pairs were used consistently across QSMRim‑Net, ResNet, and the proposed method to ensure a fair comparison.
  • Please rate the clarity and organization of this paper

    Good

  • Please comment on the reproducibility of the paper. Please be aware that providing code and data is a plus, but not a requirement for acceptance.

    The submission does not mention open access to source code or data, but provides a clear and detailed description of the algorithm to ensure reproducibility.

  • Based on your review and your understanding of the MICCAI Scientific Code of Ethics, do you believe this submission may involve a potential ethics concern or violation?

    N/A

  • Optional: If you have any additional comments to share with the authors, please provide them here. Please also refer to our Reviewer’s guide on what makes a good review and pay specific attention to the different assessment criteria for the different paper categories: https://conferences.miccai.org/2026/en/REVIEWER-GUIDELINES.html
    • Given the limited amount of QSM data, generative modeling approaches for QSM‑based data augmentation could be discussed as a potential avenue to further mitigate data scarcity.
    • Section 2.1: The statement that “spatial conditioning enables localized contextual adaptation while preserving QSM as the dominant modality” would benefit from additional clarification or empirical justification.
    • Section 3.1: Please clarify whether both QSM and FLAIR images are consistently used at the lesion (connected‑component) level during classification.
    • For the self‑supervised pretraining stage, it would be useful to discuss whether larger unannotated datasets could have been leveraged to further address the limited dataset size, and if not, why this was not feasible.
  • Rate the paper on a scale of 1-6, 6 being the strongest (6-4: accept; 3-1: reject). Please use the entire range of the distribution. Spreading the score helps create a distribution for decision-making.

    (4) Weak Accept — marginally above the acceptance threshold, but would not mind if rejected, dependent on rebuttal

  • Please justify your recommendation. What were the major factors that led you to your overall score for this paper?

    My recommendation is based on the paper’s strong technical contribution and its successful application of multimodal deep learning to a clinically significant task. The authors present a well-motivated framework that effectively handles modality asymmetry and class imbalance in MS lesion classification. However, they reflect a need for greater clarity regarding experimental controls and concerns over the robustness of findings given the dataset constraints.

  • Reviewer confidence

    Confident but not absolutely certain (3)

  • [Post rebuttal] After reading the authors’ rebuttal, please state your final opinion of the paper.

    N/A

  • [Post rebuttal] Please justify your final decision from above.

    N/A



Review #3

  • Please describe the contribution of the paper

    This paper presents an algorithm to perform binary classification of multiple sclerosis paramagnetic rim lesions (PRLs) on QSM and FLAIR MRI, with particular design considerations for multi-modal fusion and handling the challenges of a small data set and highly unbalanced classification task. The main benefit shown is increased positive predictive value (precision), while maintaining sensitivity, compared to the main comparator used in the study (QSMRim-Net).

  • Please list the major strengths of the paper: you should highlight a novel formulation, an original way to use data, demonstration of clinical feasibility, a novel application, a particularly strong evaluation, or anything else that is a strong aspect of this work. Please provide details, for instance, if a method is novel, explain what aspect is novel and why this is interesting.
    • PRLs are important to identify in multiple sclerosis, so the clinical need is real and topical.
    • The choice of QSM and FLAIR as the input sequences seems reasonable and practical for clinical use.
    • The included algorithmic components make logical sense. For example, the choice of FiLM seems to make sense for this application.
    • There is a good level of detail on the algorithm and training procedures.
    • The evaluation metrics are appropriate, particularly PR AUC.
    • An ablation study on the main components is included.
  • Please list the major weaknesses of the paper. Please provide details: for instance, if you state that a formulation, way of using data, demonstration of clinical feasibility, or application is not novel, then you must provide specific references to prior work.
    • The data set is very small (88 people with MS), and due to heterogeneity of MS, is unlikely to be a “clinically representative” cohort as claimed. There is also no description of the clinical phenotypes (e.g., relapsing vs. progressive MS, etc.), which is important for assessing the suitability of the data.
    • The benefits of the algorithm shown in the paper may not hold for larger, real-world data sets.
    • Performance was only assessed at the lesion level, whereas patient-level classification is the most important task for predicting clinical progression.
    • While the proposed method is better than the main comparator, the sensitivity is still quite low (0.447), which is probably below clinical utility.
    • Statistical testing is only reported for ROC-AUC, which is not the most useful metric for highly unbalanced data.
    • One key reference (which also uses QSM and FLAIR), seems to be missing: https://arxiv.org/pdf/2303.08434
  • Please rate the clarity and organization of this paper

    Good

  • Please comment on the reproducibility of the paper. Please be aware that providing code and data is a plus, but not a requirement for acceptance.

    The authors claimed to release the source code and/or dataset upon acceptance of the submission.

  • Based on your review and your understanding of the MICCAI Scientific Code of Ethics, do you believe this submission may involve a potential ethics concern or violation?

    N/A

  • Optional: If you have any additional comments to share with the authors, please provide them here. Please also refer to our Reviewer’s guide on what makes a good review and pay specific attention to the different assessment criteria for the different paper categories: https://conferences.miccai.org/2026/en/REVIEWER-GUIDELINES.html

    N/A

  • Rate the paper on a scale of 1-6, 6 being the strongest (6-4: accept; 3-1: reject). Please use the entire range of the distribution. Spreading the score helps create a distribution for decision-making.

    (3) Weak Reject — marginally below the acceptance threshold, but would not mind if accepted, dependent on rebuttal

  • Please justify your recommendation. What were the major factors that led you to your overall score for this paper?

    The algorithm seems well thought-out, but the small data set, selective statistical testing, and missing reference make the overall validation fairly light.

  • Reviewer confidence

    Very confident (4)

  • [Post rebuttal] After reading the authors’ rebuttal, please state your final opinion of the paper.

    N/A

  • [Post rebuttal] Please justify your final decision from above.

    N/A



Author Feedback

We thank the Meta-Reviewer and the Reviewers for their constructive comments, which helped us clarify and further develop key aspects of the manuscript. We have carefully addressed the minor comments, including improving explanations where requested and adding missing literature citations. Specifically, we have expanded the description of the clinical phenotypes and revised the Introduction to incorporate the additional references highlighted by the Reviewers. This includes adding the PRL literature mentioned by Reviewer #1 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12516162/) and replacing the arXiv reference noted by Reviewer #3 with the official MICCAI 2023 publication (https://link.springer.com/chapter/10.1007/978-3-031-43895-0_72), as also suggested by the Meta-Reviewer. Furthermore, in the camera-ready manuscript, we addressed the following reviewers’ requests for clarification. -) Methodological Clarifications. As requested by Reviewer #2, we clarified that the same QSM/FLAIR input pairs were consistently used across QSMRim-Net, ResNet, and our proposed method to ensure a fair comparison in Table 1.We also explicitly state that both modalities are jointly used at the lesion level during classification. -) Spatial Conditioning. We expanded the explanation in Section 2.1 to better justify how spatial conditioning enables localized contextual adaptation while preserving QSM as the dominant modality. -) Extended Discussions. We added a discussion on potential future directions to mitigate data scarcity, including the use of generative modeling for data augmentation and the feasibility of leveraging larger unannotated datasets for self-supervised pretraining. -) Study Limitations. As pointed out by all Reviewers and the Meta-Reviewer, we acknowledged the limited size of our single-center cohort (88 people) that may limit the broader generalization of our findings. Indeed, as stated in the Conclusion Section of our camera-ready manuscript, our primary future direction is to validate the proposed framework across larger, multi-center datasets to ensure robustness to acquisition variability. -) Statistical and Patient-Level Analysis. We incorporated a more comprehensive statistical analysis of the PR-AUC metric to better reflect performance on highly imbalanced data, and we added a discussion of patient-level results, as suggested by Reviewer #3.In particular, building on the considerations reported in [https://pubmed.ncbi.nlm.nih.gov/35247730/] and adapting them to our dataset, we classify a participant as Rim-positive if the model predicts at least one Rim+ lesion. In particular, we classify a participant as Rim-positive if the model predicts at least one Rim+ lesion. Under this definition, our model yields a more balanced patient-level diagnostic profile and substantially outperforms the baseline in estimating the total chronic active lesion burden, achieving a higher Pearson correlation between predicted and ground-truth lesion counts (r = 0.755 vs. r = 0.439). To assess statistical significance for PR-AUC, we employed a 1000-replicate bootstrapping procedure on out-of-fold predictions. The resulting 95% confidence intervals confirm that the improvement of our model is statistically significant, as its interval strictly exceeds and does not overlap with that of QSMRim-Net. As suggested by the Meta-Reviewer, we did not conduct additional experiments; however, we believe these revisions significantly strengthen the context, transparency, and clarity of our work.




Meta-Review

Meta-review #1

  • Your recommendation

    Provisional Accept

  • Please justify your decision. In case you deviate from the reviewers’ recommendations, explain in detail the reasons why. In case of an invitation for rebuttal, clarify which points are important to address in the rebuttal.

    This work presents a solution to an important clinical problem, with a clinically sound methodology and a well-written manuscript. These strengths are highlighted by all reviewers. I would also like to highlight the overall high scores. That is the basis of my recommendation.

    Having said that, there are concerns (some of them shared by all reviewers) that I think should be addressed on a final manuscript. In the following sentences I highlight what I consider important issues to address, even though I would also recommend to check all the feedback from the reviewers.

    While I want to emphasise that no new experiments should be performed, I believe that the current results should be extended following reviewer suggestions. Important things to include would be an explanation of why some studies were missed and their inclusion in the introduction [R#1 and #3], acknowledgment of the limited impact of the results and generalisation due to a single cohort and low sensitivity [R#1, 2 and 3], a more thorough statistical analysis for the non-AUC metrics [R#3] and results at the patient level [R#3]. Regarding the publication mentioned by reviewer #3, I would also advise the authors to use the official publication (MICCAI 2023 paper: https://link.springer.com/chapter/10.1007/978-3-031-43895-0_72) and not the pre-print (arxiv link).



back to top